Composition and method for preparing stable unilamellar liposomal suspension
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-009/127
A61K-008/14
A61K-008/34
A61K-008/55
A61K-008/63
A61K-008/67
A61K-008/68
A61K-009/00
A61K-009/06
A61Q-019/00
A61Q-019/08
B82Y-005/00
출원번호
US-0245528
(2008-10-03)
등록번호
US-9445975
(2016-09-20)
발명자
/ 주소
Anderson, Penelope M.
출원인 / 주소
ACCESS BUSINESS GROUP INTERNATIONAL, LLC
대리인 / 주소
Brinks Gilson & Lione
인용정보
피인용 횟수 :
0인용 특허 :
102
초록▼
Compositions and methods for producing and using stable transparent to translucent unilamellar liposomal suspensions are described. The suspensions include a liposome preparation having a uniform plurality of unilamellar liposomal particles with a mean particle size between about 50 nm to about 290
Compositions and methods for producing and using stable transparent to translucent unilamellar liposomal suspensions are described. The suspensions include a liposome preparation having a uniform plurality of unilamellar liposomal particles with a mean particle size between about 50 nm to about 290 nm. The particles are suspended in an external phase composition that has a density between about 0.95 g/cc and about 1.25 g/cc, and that is present in an amount between about 30% to about 75% of the weight of the liposomal suspension. The liposome preparation is formed from an aqueous liposomal solution that includes an oil-soluble composition and a water-soluble composition. The oil-soluble composition is present at a concentration between about 5% to about 33% by weight of the liposomal solution and the water-soluble composition is present at a concentration between about 67% to about 95% by weight of the liposomal solution.
대표청구항▼
1. A method for preparing a stable translucent to transparent unilamellar liposomal suspension comprising: a. preparing an oil-soluble composition comprising i. at least one phospholipid,ii. a rigidity enhancer in an amount from about 0.02% to about 1% of the liposomal suspension and being selected
1. A method for preparing a stable translucent to transparent unilamellar liposomal suspension comprising: a. preparing an oil-soluble composition comprising i. at least one phospholipid,ii. a rigidity enhancer in an amount from about 0.02% to about 1% of the liposomal suspension and being selected from the group consisting of a sphingolipid, a ceramide, a phytosterol, a sterol and a combination thereof,iii. an antioxidant selected from the group consisting of tocopherol, derivatives of tocopherol, alpha tocopherol, tocopheryl acetate, tocopherol succinate, ascorbic acid, derivatives of ascorbic acid, tetrahexyldecyl ascorbate, butylated hydroxyl toluene, butylated hydroxyanisole, and mixtures thereof, andiv. a coupling agent for solubilizing immiscible phases of differing polarity and having a dielectric constant of about 10.5 or greater at 23° C., wherein the coupling agent is selected from the group consisting of butylene glycol, propylene glycol, hexylene glycol, and polyethylene glycol, and mixtures thereof;b. preparing a water-soluble composition;c. combining with agitation the water-soluble composition and the oil-soluble composition to form a multilamellar and multivesicular liposome preparation, wherein the water soluble composition is present in an amount from about 67% to about 95% by weight of the liposome preparation and the oil soluble composition is present in an amount from about 5% to about 33% by weight of the liposome preparation;d. converting the multilamellar and multivesicular liposome preparation to a unilamellar liposome preparation by one of high pressure microfluidization, extrusion, high speed shearing, milling, sonication, selective microchannel filtration or homogenization, wherein the unilamellar liposome preparation comprises a plurality of unilamellar liposomal particles having a unimodal size distribution with a mean particle size between about 50 to about 290 nm; ande. adding the unilamellar liposome preparation to an external phase composition that includes a viscosity promoting agent selected from thickening agents to provide the unilamellar liposomal suspension, wherein the external phase composition has a density within a range of about 1.05 g/cc to about 1.25 g/cc and a viscosity between about 2.5 cP and about 40,000 cP at a shear rate of 10 sec−1 at 21° C.; and,wherein the liposomal suspension is translucent to transparent, has a refractive index between 1.30 and 1.45 and retains its stability in neat form at temperatures between about 4° C. to about 50° C. for a period of at least 30 days, or at 21° C. for a period of at least 180 days. 2. The method of claim 1, wherein the coupling agent is butylene glycol. 3. The method of claim 1, wherein the at least one phospholipid comprises a glycerophospholipid with varying fatty acyl moieties or a sphingolipid. 4. The method of claim 1, wherein the at least one phospholipid comprises a phospholipid preparation comprising phosphatidylcholine at a concentration of between about 80% to about 95% by weight of the phospholipid preparation. 5. The method of claim 1, comprising at least two rigidity enhancers, including at least one phytosterol and at least one member selected from the group consisting of ceramide, sphingosine, and phytosphingosine. 6. The method of claim 1, wherein the weight ratio of the liposome preparation to the external phase composition is from about 0.002 to about 0.54. 7. The method of claim 1, wherein the external phase comprises glycerin at a concentration between about 35% to about 75% of the liposomal suspension. 8. The method of claim 1, wherein the unilamellar liposome preparation is lyophilized prior to suspension in the external phase composition. 9. A method for preparing a cosmetic formulation, comprising: combining the liposomal suspension of claim 1 with a cosmetically suitable matrix to form a cosmetic formulation in the form of a cream, lotion, gel, serum, tonic, emulsion, paste, or spray. 10. A translucent unilamellar liposomal suspension comprising: a liposome preparation suspended in an external phase composition, the liposome preparation comprising a plurality of unilamellar liposomal particles having a unimodal size distribution and a mean particle size between about 50 nm to about 290 nm, the liposome preparation formed from an aqueous liposomal solution comprised of an oil-soluble composition and a water-soluble composition, the oil-soluble composition at a concentration between about 5% to about 33% by weight of the liposomal solution, the water-soluble composition at a concentration between about 67% to about 95% by weight of the liposomal solution,wherein the oil-soluble composition comprises a lecithin preparation, butylene glycol, ceramide IIIB, and β-sitosterol;wherein the external phase composition comprises glycerin at a concentration between about 35% to about 75% by weight of the liposomal suspension; andwherein the liposomal suspension is translucent and has a refractive index between about 1.30 and about 1.45. 11. A stable unilamellar liposomal suspension comprising: a liposome preparation suspended in an external phase composition, the liposome preparation comprising a plurality of unilamellar liposomal particles having a unimodal size distribution and a mean particle size between about 50 nm to about 290 nm, the liposome preparation formed from an aqueous liposomal solution comprised of an oil-soluble composition and a water-soluble composition, the oil-soluble composition at a concentration between about 5% to about 33% by weight of the liposomal solution, the water-soluble composition at a concentration between about 67% to about 95% by weight of the liposomal solution,wherein the oil-soluble composition comprises at least one phospholipid, at least one rigidity enhancer, and an antioxidant, and a coupling agent for solubilizing immiscible phases of differing polarity and having a dielectric constant of about 10.5 or greater at 23° C., wherein the antioxidant is selected from the group consisting of tocopherol, derivatives of tocopherol, alpha tocopherol, ascorbic acid, derivatives of ascorbic acid, butylated hydroxyl toluene, butylated hydroxyanisole, and mixtures thereof, wherein the at least one rigidity enhancer is selected from the group consisting of sphingolipid, phytosterol, cholesterol, and mixtures thereof and wherein the coupling agent is selected from the group consisting of butylene glycol, propylene glycol, hexylene glycol, and polyethylene glycol, and mixtures thereof;wherein the external phase composition is at a concentration between about 30% to about 75% by weight of the liposomal suspension, the external phase composition comprising a viscosity promoting agent selected from thickening agents and having a density between about 0.95 g/cc and about 1.25 g/cc and a viscosity between about 2.5 cP and about 40,000 cP at a shear rate of 10 sec−1 at 21° C.; andwherein the liposomal suspension is translucent to transparent, has a refractive index between about 1.30 and about 1.45, and retains its stability in neat form at a temperature of between about 4° C. to about 50° C. for a period of at least 30 days or at 21° C. for a period of at least 180 days. 12. The liposomal suspension of claim 11, wherein the coupling agent is butylene glycol. 13. The liposomal suspension of claim 11, wherein the at least one phospholipid comprises a glycerophospholipid with varying fatty acyl moieties or a sphingomyelin. 14. The liposomal suspension of claim 11, wherein the at least one phospholipid comprises a phospholipid preparation comprising phosphatidylcholine at a concentration of between about 80% to about 95% by weight of the phospholipid preparation. 15. The liposomal suspension of claim 11, comprising at least two rigidity enhancers, including at least one phytosterol and at least one member selected from the group consisting of ceramide, sphingosine, and phytosphingosine. 16. The liposomal suspension of claim 11, wherein the oil-soluble composition comprises butylene glycol, ceramide IIIB, β-sitosterol, and tocopherol. 17. The liposomal suspension of claim 11, wherein the liposomal suspension comprises glycerin at a concentration between about 35% to about 75% of the liposomal suspension.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (102)
Chakrabarti Ajoy (Vancouver CAX) Clark-Lewis Ian (Vancouver CAX) Cullis Pieter R. (Vancouver CAX), Accumulations of amino acids and peptides into liposomes.
Janoff Andrew S. (Yardley PA) Bolcsak Lois E. (Lawrenceville NJ) Weiner Alan L. (Lawrenceville NJ) Tremblay Paul A. (Hamilton NJ) Bergamini Michael V. W. (Easton PA), Alpha tocopherol-based vesicles.
Bombardelli Ezio (Milan ITX) Patri Gianfranco (Milan ITX) Pozzi Roberto (Milan ITX), Complexes of saponins and their aglycons with phospholipids and pharmaceutical and cosmetic compositions containing them.
Bonte Frederic (Courbevoie FRX) Meybeck Alain (Courbevoie FRX) Marechal Christian (Paris FRX), Composition based upon hydrated lipidic lamellar phases or liposomes containing at least one derivative of labdane.
Handjani Rose M. (Paris FRX) Ribier Alain (Paris FRX) Vanlerberghe Guy (Villevaude FRX) Zabotto Arlette (Paris FRX) Griat Jacqueline (Ablon FRX), Cosmetic and pharmaceutical compositions containing niosomes and a water-soluble polyamide, and a process for preparing.
Meybeck Alain (Courbevoie FRX) Bonte Frdric (Courbevoie FRX) Dumas Marc (Colombes FRX), Cosmetic or pharmaceutical composition, especially dermatological composition, intended for promoting the pigmentation o.
Adrienne Elizabeth Clarke AU; Antony Bacic AU; Alan Gordon Lane AU, Cultured plant cell gums for food, pharmaceutical, cosmetic and industrial applications.
Cullis Pieter R. (Vancouver CAX) Hope Michael J. (Vancouver CAX) Bally Marcel B. (Vancouver CAX), Extrusion technique for producing unilamellar vesicles.
Schneider Michel (Troinex CHX) Tournier Herv (Valleiry FRX) Hyacinthe Roland (Aubonne FRX) Guillot Christian (Le Chable-Beaumont FRX) Lamy Bernard (Geneva CHX), Method for making liposomes of enhanced entrapping capacity toward foreign substances to be encapsulated.
Janoff Andrew S. (Yardley PA) Bolcsak Lois E. (Lawrenceville NJ) Weiner Alan L. (Lawrenceville NJ) Tremblay Paul A. (Hamilton NJ) Bergamini Michael V. W. (Easton PA), Method for preparing alpha-tocopherol vesicles.
Denis Alain (Loges FRX) Kieda Claudine (Orleans FRX) Monsigny Michel (Saint Cyr En Val FRX) Perrier Pierre (Orleans FRX) Redziniak Grard (Saint Cyr En Val FRX), Method of binding a product to the membrane of a keratinocyte by means of a ligand-receptor bond, method of preparing su.
Varanelli Carol (Chester NH) Kumar Surendra (Vineland NJ) Wallach Donald F. H. (Hollis NH), Method of inhibiting viral reproduction using non-phospholipid, paucilamellar liposomes.
Tremblay Paul A. (Hamilton NJ) Suddith Robert L. (Robbinsville NJ) Kearns John J. (Princeton NJ), Phospholipid composition and liposomes made therefrom.
Frederiksen Lene (Basel CHX) Anton Klaus (Basel CHX) van Hoogevest Peter (Riehen CHX), Process for the preparation of a liposome dispersion under elevated pressure contents.
Voegeli Rainer (Bubendorf CHX) Stocker Kurt (Aesch CHX) Mueller Christian (Reinach CHX), Protein fraction for cosmetic and dermatology care of the skin.
Wheeler Edward L. (Fairfield NJ) D\Amelia Ronald P. (Hicksville NY) Leveille Gilbert A. (Denville NJ) Otterburn Michael S. (Randolph NJ) Klemann Lawrence P. (Somerville NJ) Finley John W. (Whippany N, Reduced calorie triglyceride mixtures.
Aust Duncan T. ; Ross Michael A. ; Wilmott James M. ; Hayward James A., Stabilizing vitamin A derivatives by encapsulation in lipid vesicles formed with alkylammonium fatty acid salts.
Mentrup Edgar (Frankfurt DEX) Michel Christoph (Obertshausen DEX) Purmann Thomas (Aschaffenburg DEX), Stable small particle liposome preparations, their production and use in topical cosmetic, and pharmaceutical compositio.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.